Matches in SemOpenAlex for { <https://semopenalex.org/work/W2408049887> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W2408049887 endingPage "8" @default.
- W2408049887 startingPage "2225" @default.
- W2408049887 abstract "Plachitin formed of both poly-N-acetyl-D-glucosamine (chitin) and cis-diamminedichloroplatinum (CDDP), was used as an arterial chemoembolization therapy against unresectable liver cancer. One gram of Plachitin contained 300 mg of CDDP. The Plachitin particle was 50-100 microns in diameter. Plachitin particles (50-100 mg) were injected via hepatic artery once or twice every week, and the total amount of 300 mg was considered one course of this therapy. The size and number of tumors were measured by computer tomography (CT). Pharmacokinetics of this drug was also assessed by serum and urine platinum (Pt) concentration. Three patients underwent the chemoembolization therapy using plachitin particles. Case 1 had multiple hepatocellular carcinomas. The tumor regression rate was 39% after two courses of this therapy. Serum alpha-fetoprotein (AFP) level decreased from 1,182 ng/ml to 300 ng/ml. Case 2 suffered from bile duct cystadenocarcinoma. After three courses of the therapy, the tumor regression rate was 84.4%. Serum carbohydrate antigen 19-9 (CA19-9) decreased from 731 U/ml to 75 U/ml. Case 3 had synchronous multiple liver metastases from sigmoid colon cancer. The tumor regression rate was 77% after one course of the therapy. Carcinoembryonic antigen (CEA) and CA19-9 decreased from 406 ng/ml to 65 ng/ml and from 4,800 U/ml to 790 ng/ml, respectively. The response rate of the 3 cases was 66.7%. The peak levels of the serum Pt concentration of three patients were 0-0.4 microgram/g throughout the therapy, but peak urine Pt concentrations were observed during one course of the therapy of three patients ranging from 0.5 microgram/g to 3.2 micrograms/g, and decreased gradually for three weeks after the first course. Adverse effects of Plachitin particles for arterial chemoembolization were epigastralgia, nausea, fever, and elevation of serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels. These adverse effects were observed in all patients, but were transient. Catheter obstruction occurred in one patient (case 2). Cholecystitis, pancreatic pseudocyst, and duodenal ulcer were noticed in case 3. No renal hypofunction was observed. Plachitin might be a useful agent for arterial chemoembolization therapy for primary and secondary liver cancer." @default.
- W2408049887 created "2016-06-24" @default.
- W2408049887 creator A5028119987 @default.
- W2408049887 creator A5030048967 @default.
- W2408049887 creator A5040593295 @default.
- W2408049887 creator A5055325607 @default.
- W2408049887 creator A5064345727 @default.
- W2408049887 creator A5087401844 @default.
- W2408049887 date "1994-09-01" @default.
- W2408049887 modified "2023-09-23" @default.
- W2408049887 title "[Intraarterial chemoembolization therapy for unresectable liver cancer using plachitin particles]." @default.
- W2408049887 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7944446" @default.
- W2408049887 hasPublicationYear "1994" @default.
- W2408049887 type Work @default.
- W2408049887 sameAs 2408049887 @default.
- W2408049887 citedByCount "1" @default.
- W2408049887 crossrefType "journal-article" @default.
- W2408049887 hasAuthorship W2408049887A5028119987 @default.
- W2408049887 hasAuthorship W2408049887A5030048967 @default.
- W2408049887 hasAuthorship W2408049887A5040593295 @default.
- W2408049887 hasAuthorship W2408049887A5055325607 @default.
- W2408049887 hasAuthorship W2408049887A5064345727 @default.
- W2408049887 hasAuthorship W2408049887A5087401844 @default.
- W2408049887 hasConcept C112705442 @default.
- W2408049887 hasConcept C121608353 @default.
- W2408049887 hasConcept C126322002 @default.
- W2408049887 hasConcept C2776231280 @default.
- W2408049887 hasConcept C2777387746 @default.
- W2408049887 hasConcept C2778019345 @default.
- W2408049887 hasConcept C2989005 @default.
- W2408049887 hasConcept C71924100 @default.
- W2408049887 hasConcept C90924648 @default.
- W2408049887 hasConceptScore W2408049887C112705442 @default.
- W2408049887 hasConceptScore W2408049887C121608353 @default.
- W2408049887 hasConceptScore W2408049887C126322002 @default.
- W2408049887 hasConceptScore W2408049887C2776231280 @default.
- W2408049887 hasConceptScore W2408049887C2777387746 @default.
- W2408049887 hasConceptScore W2408049887C2778019345 @default.
- W2408049887 hasConceptScore W2408049887C2989005 @default.
- W2408049887 hasConceptScore W2408049887C71924100 @default.
- W2408049887 hasConceptScore W2408049887C90924648 @default.
- W2408049887 hasIssue "13" @default.
- W2408049887 hasLocation W24080498871 @default.
- W2408049887 hasOpenAccess W2408049887 @default.
- W2408049887 hasPrimaryLocation W24080498871 @default.
- W2408049887 hasRelatedWork W2367543438 @default.
- W2408049887 hasRelatedWork W2407531899 @default.
- W2408049887 hasRelatedWork W2992614046 @default.
- W2408049887 hasRelatedWork W3025490003 @default.
- W2408049887 hasRelatedWork W3028626473 @default.
- W2408049887 hasRelatedWork W3029896082 @default.
- W2408049887 hasRelatedWork W3030616408 @default.
- W2408049887 hasRelatedWork W3031967535 @default.
- W2408049887 hasRelatedWork W3032120761 @default.
- W2408049887 hasRelatedWork W3083338011 @default.
- W2408049887 hasVolume "21" @default.
- W2408049887 isParatext "false" @default.
- W2408049887 isRetracted "false" @default.
- W2408049887 magId "2408049887" @default.
- W2408049887 workType "article" @default.